References
1. GINA Committee. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020. URL: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-Appendix_final-wms.pdf (date of access October 14, 2021)
2. Soriano J.B., Abajobir A.A., Abate K.H., Abera S.F., et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5: 691–706. DOI: http://doi.org/10.1016/S2213-2600(17)30293-X
3. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., Petrakovskaya V.A., Izyumova G.V. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pul’monologiya. 2018; 28: 341–58. DOI: http://doi.org/10.18093/0869-0189-2018-28-3-341-358 (in Russian)
4. Moote W., Kim H., Ellis A.K. Allergen-specific immunotherapy. Allergy Asthma Clin. Immunol. 2018; 14: 1–10. DOI: http://doi.org/10.1186/s13223-018-0282-5
5. Pavlova K.S., Kurbacheva O.M., Galitskaya M.A., Smirnov D.S. Actual conception of allergen-specific immunotherapy mechanisms, potential biomarkers of efficacy and ways of enhancement. Rossiyskiy allergologicheskiy zhurnal. 2017; 14: 5–17. DOI: http://doi.org/10.36691/RJA290 (in Russian)
6. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., Harris J.M., Scheerens H., Wu L.C., Su Z., Mosesova S., Eisner M.D., Bohen S.P., Matthews J.G. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 2011; 365: 1088–98. DOI: http://doi.org/10.1056/NEJMoa1106469
7. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18: 716–25. DOI: http://doi.org/10.1038/nm.2678
8. Seys S.F., Lokwani R., Simpson J.L., Bullens D.M.A. New insights in neutrophilic asthma. Curr. Opin. Pulm. Med. 2019; 25: 113–20. DOI: http://doi.org/10.1097/MCP.0000000000000543
9. Liu W., Liu S., Verma M., Zafar I., Good J.T., Rollins D., Groshong S., Gorska M.M., Martin R.J., Alam R. Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J. Allergy Clin. Immunol. 2017; 139: 1548–58. DOI: http://doi.org/10.1016/j.jaci.2016.08.032
10. Chaudhry A., Rudra D., Treuting P., Samstein R.M., Liang Y., Kas A., Rudensky A.Y. CD4+ regulatory T cells control Th17 responses in a STAT3-dependent manner. Science. 2009; 326: 986–91. DOI: http://doi.org/10.1126/science.1172702
11. Halwani R., Sultana A., Vazquez-Tello A., Jamhawi A., Al-Masri A.A., Al-Muhsen S. Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma. J. Asthma. 2017; 54: 893–904. DOI: http://doi.org/10.1080/02770903.2017.1283696
12. Shilovskiy I.P., Nikolskii A.A., Kurbacheva O.M., Khaitov M.R. Modern view of neutrophilic asthma molecular mechanisms and therapy. Biochemistry (Mosc). 2020; 85: 854–68. DOI: http://doi.org/10.1134/S0006297920080027
13. Saw P.E., Song E.W. siRNA therapeutics: a clinical reality. Sci. China Life Sci. 2020; 63: 485–500. DOI: http://doi.org/10.1007/s11427-018-9438-y
14. Nikam R.R., Gore, K.R. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018; 28: 209–24. DOI: http://doi.org/10.1089/nat.2017.0715
15. Koloskova O.O., Nosova A.S., Sebyakin Y.L., Ilyukhina A.A., Shilovskiy I.P., Khaitov M.R. Liposomal siRNA delivery systems (review). Russ. J. Biopharm. 2017; 9: 3–10.
16. Kozhikhova K.V, Andreev S.M., Shilovskiy I.P., Timofeeva A.V, Gaisina A.R., Shatilov A.A., Turetskiy E.A., Andreev I.M., Smirnov V.V, Dvornikov A.S., Khaitov M.R. A novel peptide dendrimer LTP efficiently facilitates transfection of mammalian cells. Org. Biomol. Chem. 2018; 16: 8181–90. DOI: http://doi.org/10.1039/c8ob02039f
17. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013; 12: 967–77. DOI: http://doi.org/10.1038/nmat3765
18. Shilovskiy I.P., Nikolskii A.A., Kovchina V.I., Bolotova S.I., Vishniakova L.I., Sokolova A.R., Barvinskaya E.D., Khaitov M.R. Activation of Th17-immune response in a mouse model of neutrophilic asthma. Immunologiya. 2019; 40: 5–15. DOI: http://doi.org/10.24411/0206-4952-2019-16001 (in Russian)
19. Lu Z.J., Mathews D.H. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res. 2008; 36: 104–8. DOI: http://doi.org/10.1093/nar/gkn250
20. Shilovskiy I.P., Sundukova M.S., Babakhin А.А., Gaisina A.R., Maerle A.V., Sergeev I.V., Nikolskiy A.A., Barvinckaya E.D., Kovchina V.I., Kudlay D.A., Nikonova A.A., Khaitov M.R. Experimental protocol for development of adjuvant-free murine chronic model of allergic asthma. J. Immunol. Methods. 2019; 468: 10–9. DOI: http://doi.org/10.1016/j.jim.2019.03.002
21. Chang H.S., Lee T.H., Jun J.A., Baek A.R., Park J.S., Koo S.M., Kim Y.K., Lee H.S., Park C.S. Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations. Expert Rev. Respir. Med. 2017; 11: 29–40. DOI: http://doi.org/10.1080/17476348.2017.1268919
22. Newcomb D.C., Peebles R.S. Th17-mediated inflammation in asthma. Curr. Opin. Immunol. 2013; 25: 755–760. DOI: http://doi.org/10.1016/j.coi.2013.08.002
23. Steinke J.W., Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2001; 2: 66–70. DOI: http://doi.org/10.1186/rr40
24. Miyajima I., Dombrowicz D., Martin T.R., Ravetch J.V, Kinet J.P., Galli S.J. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J. Clin. Invest. 1997; 99: 901–14. DOI: http://doi.org/10.1172/JCI119255
25. Oettgen H.C., Martin T.R., Wynshaw-Boris A., Deng C., Drazen J.M., Leder P. Active anaphylaxis in IgE-deficient mice. Nature. 1994; 370: 367–70. DOI: http://doi.org/10.1038/370367a0
26. Juliano R.L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016; 44: 6518–48. DOI: http://doi.org/10.1093/nar/gkw236
27. Lim H., Cho M., Choi G., Na H., Chung Y. Dynamic control of Th2 cell responses by STAT3 during allergic lung inflammation in mice. Int. Immunopharmacol. 2015; 28: 846–53. DOI: http://doi.org/10.1016/j.intimp.2015.03.051
28. Simeone-Penney M.C., Severgnini M., Tu P., Homer R.J., Mariani T.J., Cohn L., Simon A.R. Airway epithelial STAT3 is required for allergic inflammation in a murine model of asthma. J. Immunol. 2007; 178: 6191–9. DOI: http://doi.org/10.4049/jimmunol.178.10.6191